This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04839042
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : August 22, 2023
Sponsor:
Information provided by (Responsible Party):
Moat Biotechnology Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route in healthy volunteers.

Condition or disease Intervention/treatment Phase
Covid19 Biological: SC-Ad6-1 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 190 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular, Intranasal or Inhaled Administration in Healthy Volunteers
Actual Study Start Date : June 28, 2021
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: SC-Ad6-1 Low Dose Intramuscular
Low Dose SC-Ad6-1, I.M., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 Medium Dose Intramuscular
Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #1 Intramuscular
High Dose #1 SC-Ad6-1, I.M., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #2 Intramuscular
High Dose #2 SC-Ad6-1, I.M., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 Multiple Dose Intramuscular
Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #3 Intramuscular Booster
High Dose #3 SC-Ad6-1, I.M., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.M., single or multiple-dose
Experimental: SC-Ad6-1 Low Dose Intranasal
Low Dose SC-Ad6-1, I.N., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 Medium Dose Intranasal
Medium Dose SC-Ad6-1, I.N., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #1 Intranasal
High Dose #1 SC-Ad6-1, I.N., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #2 Intranasal
High Dose #2 SC-Ad6-1, I.N., single-dose (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 Multiple Dose Intranasal
Multiple Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 22)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #3 Intranasal Booster
High Dose #3 SC-Ad6-1, I.N., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 High Dose #4 Intranasal Booster
High Dose #4 SC-Ad6-1, I.N., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.N., single or multiple-dose
Experimental: SC-Ad6-1 Low Dose Inhaled
Low Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.H., single or multiple-dose
Experimental: SC-Ad6-1 Medium Dose Inhaled
Medium Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.H., single or multiple-dose
Experimental: SC-Ad6-1 High Dose Inhaled
High Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
 Biological: SC-Ad6-1
SC-Ad6-1, I.H., single or multiple-dose


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants with solicited local and systemic adverse events for 7 days Following Each Dose [ Time Frame: 7 days following each dose ]
    Solicited local adverse events are defined as pain, redness and swelling at the site of dose administration for the intramuscular arms, are defined as stuffy nose, runny nose, nasal discomfort, loss of smell, sore or scratchy throat for the intranasal arms and are defined as stuffy nose, runny nose, dry mouth, mouth sores, sore or scratchy throat and cough for the inhalation arms. Solicited systemic adverse events for all routes of administration are defined as fever, headache, muscle pain, joint pain, fatigue, nausea or vomiting, and chills.

  2. Incidence and severity of adverse events (AEs), including withdrawals due to safety or tolerability reasons [ Time Frame: Up to 106 days following first dose ]
  3. Humoral response to SARS-CoV-2 as measured by neutralizing antibodies using wild-type virus assay [ Time Frame: Up to 106 days following first dose ]

Secondary Outcome Measures :
  1. Humoral response to SARS-CoV-2 as measured by serum IgG and IgA antibodies to the SARS-CoV-2 spike protein (ELISA) [ Time Frame: Up to 106 days following first dose ]
  2. Humoral response to SARS-CoV-2 as measured by mucosal IgA antibodies to the SARS-CoV-2 spike protein (ELISA) and total mucosal IgA [ Time Frame: Up to 106 days following first dose ]
  3. Measurement of cytokine-producing T cells specific for the SARS-CoV-2 spike protein (ELISpot) [ Time Frame: Up to 106 days following first dose ]
  4. Measurement of adenovirus 6 (Ad6) neutralizing antibodies (anti-drug antibodies (ADA)) [ Time Frame: Up to 106 days following first dose ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Adult males and females, 18 to 60 years of age (inclusive)
  • Body mass index ≥ 18.0 and ≤ 32.0 kg/m2, with a body weight ≥ 50 kg at screening
  • Must have been fully vaccinated against COVID-19 and received last dose not less than 3 months prior to Day 1 (High Dose #3 I.M. and I.N. booster arms only), not less than 5 months prior to Day 1 (High Dose #4 I.N. booster arm only) and not less than 6 months prior to Day 1 (I.H. booster arms only)

Key Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease
  • History of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to Screening) or ongoing respiratory tract infection
  • History of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members
  • History of any neurological disorders or seizures including Guillain-Barre syndrome, with the exception of febrile seizures during childhood
  • Known previous infection with SARS-CoV-2 or presence of antibodies against SARS-CoV-2 or a positive SARS-CoV-2 PCR test (non-booster arms only)
  • Any history of malignant disease ≤5 years prior to registration
  • History of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04839042


Contacts
Layout table for location contacts
Contact: Russell Rother, Ph.D. 855-222-0722 rrother@tetherex.com

Locations
Layout table for location information
Australia, Queensland
Tetherex Study Site Recruiting
Brisbane, Queensland, Australia
Sponsors and Collaborators
Moat Biotechnology Corporation
Investigators
Layout table for investigator information
Study Director: Russell Rother, Ph.D. Moat Biotechnology Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Moat Biotechnology Corporation
ClinicalTrials.gov Identifier: NCT04839042    
Other Study ID Numbers: SC-Ad6-1-002
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: August 22, 2023
Last Verified: August 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
 Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Cloricromen
Platelet Aggregation Inhibitors